Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 31 n°22

Posts Tagged ‘healthcare’

37th Annual J.P. Morgan Healthcare Conference

Posted by fidest press agency su giovedì, 3 gennaio 2019

San Francisco on Wednesday, January 9, 2019 Time: 11:00 a.m. PT Westin St. Francis, Elizabethan D. Merck (NYSE:MRK), Morphic Therapeutic, a biotechnology company developing a new generation of oral integrin therapies, announced today that the company will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco Praveen Tipirneni, M.D., president and CEO of Morphic, will provide an overview of the company, its innovative platform for designing integrin oral inhibitors, and anticipated milestones in 2019.Morphic is developing highly differentiated molecules for the treatment of autoimmune diseases, fibrotic diseases, and cancer. In 2018, Morphic announced the completion of a $80 million Series B financing and entered into a research and development collaboration with AbbVie designed to advance a number of Morphic’s oral integrin therapeutics for fibrosis-related indications.

Posted in Estero/world news | Contrassegnato da tag: , | Leave a Comment »

The Future of AI-Powered Healthcare session and reception

Posted by fidest press agency su giovedì, 3 gennaio 2019

Parc 55 San Francisco, Monday, January 7, 4 pm 55 Cyril Magnin Street; 4th Floor, Cyril Magnin Ballroom. The newly formed Alliance for Artificial Intelligence in Healthcare (AAIH) is sponsoring a panel discussion open to the public, titled “The Future of AI-Powered Healthcare,” on Monday, January 7, in association with the Digital and Medtech Medicine Showcase at the Biotech Showcase in San Francisco. Experts will explore not only the potential impact of machine learning on healthcare systems and drug development, but also provide insights on what investors and partners should consider before engaging in financing or co-development with AI healthcare companies.Preceding the panel, Alex Zhavoronkov, CEO of Insilico Medicine, will provide an introduction, announcing the official launch of AAIH, which will include the organization’s inaugural board meeting on Wednesday, January 9, in San Francisco.
Panelists are Alex Lash, National Biotech Editor, Xconomy; Brandon Allgood, CTO and Co-founder of Numerate; John Baldoni, Senior VP of In-Silico Drug Discovery, GSK; Maria Luisa Pineda, CEO and Co-Founder, Envisagenics; Bill Martin, President and COO, BlackThorn Therapeutics; Angeli Moeller, Co-Lead of AI, Head of Research IT Business Partnering, Bayer; and Ben Newton, CDO, GE Healthcare Life Sciences.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

37th Annual J.P. Morgan Healthcare Conference

Posted by fidest press agency su domenica, 23 dicembre 2018

Novocure (NASDAQ: NVCR) will participate in the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 9, 2019, in San Francisco. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts. He is scheduled to present at 2:30 p.m. PST.A live audio webcast of the presentation and all presentation materials can be access from the Investor Relations page of Novocure’s website, http://www.novocure.com/investor-relations/, and will be available for replay for at least 14 days following the event.Novocure is an oncology company developing a profoundly different cancer treatment utilizing a proprietary therapy called Tumor Treating Fields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure’s commercialized product is approved for the treatment of adult patients with glioblastoma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and mesothelioma.Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. Additionally, the company has offices in Germany, Switzerland, Japan and Israel. For additional information about the company, please visit http://www.novocure.com or follow us at http://www.twitter.com/novocure.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

37th Annual J.P. Morgan Healthcare Conference

Posted by fidest press agency su venerdì, 21 dicembre 2018

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 8, 2019 at 11:30 a.m. Pacific Time (PT). The presentation will be followed by a Q&A session at noon PT.
The presentation and Q&A session will be webcast live and may be accessed through the investors section of Hologic’s website at http://investors.hologic.com. The webcasts will be available for 30 days.
Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit http://www.hologic.com

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Cross Country Healthcare to Attend J.P. Morgan’s 37th Annual Healthcare Conference

Posted by fidest press agency su sabato, 15 dicembre 2018

Cross Country Healthcare, Inc. (Nasdaq:CCRN) announced today that Christopher R. Pizzi, Senior Vice President and Chief Financial Officer, will be attending J.P. Morgan’s 37th Annual Healthcare Conference on January 7-10, 2019 at The Westin St. Francis Hotel in San Francisco, California. No formal presentation will be made by Cross Country Healthcare, Inc. at this conference.
Cross Country Healthcare is a national leader in providing innovative healthcare workforce solutions and staffing services. Our solutions leverage our nearly 40 years of expertise and insight to assist clients in solving complex labor-related challenges while maintaining high quality outcomes. We are dedicated to recruiting and placing highly qualified healthcare professionals in virtually every specialty and area of expertise. Our diverse client base includes both clinical and nonclinical settings, servicing acute care hospitals, physician practice groups, outpatient and ambulatory-care centers, nursing facilities, both public schools and charter schools, rehabilitation and sports medicine clinics, government facilities, and homecare. Through our national staffing teams and network of 70 office locations, we are able to place clinicians on travel and per diem assignments, local short-term contracts and permanent positions. We are a market leader in providing flexible workforce management solutions, which include managed services programs (MSP), internal resource pool consulting and development, electronic medical record (EMR) transition staffing, recruitment process outsourcing, predictive modeling and other outsourcing and consultative services. In addition, we provide both retained and contingent placement services for healthcare executives, physicians, and other healthcare professionals.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Healthcare in Time of a Disaster

Posted by fidest press agency su mercoledì, 28 novembre 2018

While no two disasters are alike, preparation and response for disasters have many similarities and are key to delivering everything from healthcare services to vital resources. These issues will take center stage at the International Conference on Disaster Medicine and Hurricane Resiliency. Healthcare professionals and educators, and persons focused on emergency response and training will converge on Sint Maarten in March for the conference being hosted by American University of the Caribbean School of Medicine (AUC).
The conference, taking place March 8 – 11, 2019, is being organized by AUC in cooperation with Harvard Medical Faculty Physicians of Beth Israel Deaconess Medical Center (HMFP), a physician group that includes emergency medicine experts with global disaster medicine experience. For full conference details and online registration visit: https://ccdm.aucmed.edu.AUC and HMFP are currently working together to develop the Caribbean Center for Disaster Medicine (CCDM), which will be based in Sint Maarten. The CCDM will be center of excellence designed to foster collaboration among professionals responsible for healthcare delivery, disaster preparedness, emergency response and medical education in the region.
AUC is part of an alliance of medical and healthcare educational institutions operated by Adtalem Global Education, which educate doctors, nurses, veterinarians and other health care professionals. With a presence in North America, the Caribbean, the United Kingdom and Brazil, Adtalem institutions provide global resources, clinical partners and leadership in an array of healthcare disciplines to support the Caribbean Center for Disaster Medicine, including One Health Foundation and research facilities that address the intersection of animal, human and environmental health.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Hologic to Webcast Presentation at the 30th Annual Piper Jaffray Healthcare

Posted by fidest press agency su lunedì, 19 novembre 2018

Conference Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the 30th Annual Piper Jaffray Healthcare Conference in New York, NY on Wednesday, November 28 at 8 a.m. Eastern Time. The presentation will be webcast live and may be accessed through a link on the investors section of Hologic’s website at http://investors.hologic.com. The webcast will be available for 30 days following the event.Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit http://www.hologic.com

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Intersect ENT to Present at the Piper Jaffray 30th Annual Healthcare Conference

Posted by fidest press agency su venerdì, 9 novembre 2018

Intersect ENT, Inc. (Nasdaq:XENT) today announced that management will participate in the 30th Annual Piper Jaffray Health Care Conference on November 28 at the Lotte New York Palace in New York City, and will present in a session at 10:30am ET.
A replay of the session will be available via the investors section of the company’s website at http://www.intersectENT.com. The webcast replay will be archived for approximately one month.
Intersect ENT is dedicated to transforming ear, nose and throat care by providing innovative, clinically meaningful therapies to physicians and patients. The company’s steroid releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease. In addition, Intersect ENT is continuing to expand its portfolio of products based on the company’s unique localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost-effective care.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Kala Pharmaceuticals to Present at the Jefferies 2018 London Healthcare Conference

Posted by fidest press agency su venerdì, 9 novembre 2018

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced that it will present at the Jefferies 2018 London Healthcare Conference in London, U.K.. Todd Bazemore, Chief Operating Officer at Kala Pharmaceuticals, will provide a corporate overview on Wednesday, November 14, 2018 at 2:00 PM GMT.
Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY mucus-penetrating particle (MPP) Drug Delivery Technology, with an initial focus on the treatment of eye diseases. Kala has applied the AMPPLIFY Drug Delivery Technology to a corticosteroid, loteprednol etabonate (LE), designed for ocular applications, resulting in recently approved INVELTYSTM (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery and its lead product candidate, KPI-121 0.25%, for the temporary relief of the signs and symptoms of dry eye disease.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

IQVIA to Present at the Credit Suisse Annual Healthcare Conference on November 13, 2018

Posted by fidest press agency su giovedì, 8 novembre 2018

IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV), announced today that Michael McDonnell, executive vice president and chief financial officer, will speak at the Credit Suisse 27th Annual Healthcare Conference in Scottsdale, AZ on Tuesday, November 13, 2018 at 1:40 p.m. MST / 3:40 p.m. EST.A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com. A replay of the webcast also will be available later that day.
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With more than 55,000 employees, IQVIA conducts operations in more than 100 countries.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing the information that helps its customers drive human health outcomes forward. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers, and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors, and scientific advances, in an effort to advance their path toward cures. To learn more, visit http://www.iqvia.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Exelixis to Present at the Stifel 2018 Healthcare Conference on November 13, 2018

Posted by fidest press agency su giovedì, 8 novembre 2018

Exelixis, Inc. (NASDAQ: EXEL) announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide an overview of the company at the Stifel 2018 Healthcare Conference taking place November 13-14 in New York, NY. The Exelixis presentation is scheduled for 10:15 AM EST / 7:15 AM PST on Tuesday, November 13, 2018.
To access the webcast link, log onto http://www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to listen to the webcast. A replay will also be available at the same location for 14 days.
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model genetic systems, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. We discovered our three commercially available products, CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib) and COTELLIC® (cobimetinib), and have entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Cerus to Present at the Baird 2018 Global Healthcare Conference

Posted by fidest press agency su lunedì, 3 settembre 2018

Cerus Corporation (Nasdaq: CERS) today announced that Kevin D. Green, Cerus’ vice president, finance and chief financial officer, will present and provide a corporate update at the Baird 2018 Global Healthcare Conference in New York City on Thursday, September 6, 2018 at 8:30 a.m. ET.A live webcast of the presentation will be available from the Investor Relations page of the Cerus web site at http://www.cerus.com/ir. A replay will be available for approximately two weeks following the completion of the event.Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT Red Blood Cell system is in clinical development. See http://www.cerus.com for information about Cerus.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Infolock Kicks Off 3rd Annual Healthcare IT Security Leaders’ Summit

Posted by fidest press agency su domenica, 26 agosto 2018

Today, leading data advisory consulting firm Infolock kicked off its third annual Healthcare IT Security Leaders’ Summit at its corporate headquarters outside Washington, DC. The two-day, invite-only conference brings together IT and information security executives and industry experts and covers topics including blockchain applications for the healthcare industry, HIPAA enforcement, the future of AI in clinical settings, GDPR regulatory compliance and data privacy, managing privilege attacks, user-entity behavioral analytics, and other topics.When asked about the event, Ryan Dobbins, director of advisory services for Infolock said, “It’s a remarkable and unique experience for us to host the Summit, and we routinely hear from our attendees that it’s the best conference or meeting they attend all year long. That’s incredibly gratifying for us. We’re laser focused on avoiding vendor marketing in the subject matter presented — something we feel ruins other similar events — and it clearly shows in the quality and vigor of the dialogue we spark between and among participants. We think the industry needs more probing, challenging conversations and fewer long-form commercials.” Speakers from the U.S. Department of Health and Human Services’ Office of Civil Rights, Community Health Systems, The Center for Internet Security, the Virginia Modeling, Analysis, and Simulation Center at Old Dominion University, Polsinelli, BeyondTrust, Bay Dynamics, and Infolock will present over the course of two days. Attendees include executives from Penn Medicine, Sentara Healthcare, Temple University Health System, Orthofix, Gateway Health, Augusta Health, Valley Health, and others. In response to a question about previous years’ events and their most valuable insights, attendee Michael Bray, senior director of information security and compliance at Community Health Systems in Franklin, TN said, “Having the opportunity to hear directly from HHS OCR regarding breach reporting and enforcement, and getting the legal community’s perspective on effective breach response, was invaluable.”

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Arcus Biosciences to Participate in the 2018 Wedbush PacGrow Healthcare Conference

Posted by fidest press agency su domenica, 5 agosto 2018

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that Terry Rosen, Ph.D., Chief Executive Officer, will participate in a fireside chat at the 2018 Wedbush PacGrow Healthcare Conference on Tuesday, August 14, 2018 at 2:30 pm ET at the Parker New York, in New York City, NY. Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies. Arcus has several programs targeting important immuno-oncology pathways, including a dual adenosine receptor antagonist AB928, which is being evaluated in combination with other agents in multiple tumor types in a Phase 1/1b program, and an anti-PD-1 antibody AB122, which is being evaluated in a Phase 1 trial and will be tested in combination with Arcus’s other product candidates. Arcus’s other programs include an anti-TIGIT antibody AB154, which is in a phase 1 program, and a small molecule inhibitor of CD73 AB680, which is in IND-enabling studies. Arcus has extensive in-house expertise in medicinal chemistry, immunology, biochemistry, pharmacology and structural biology. For more information about Arcus Biosciences, please visit http://www.arcusbio.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

NextGen Healthcare to Present at Upcoming Investor Conferences

Posted by fidest press agency su venerdì, 25 maggio 2018

Quality Systems, Inc. (NASDAQ: QSII), known to its clients as NextGen Healthcare, announced today that President and Chief Executive Officer, Rusty Frantz, and Chief Financial Officer, Jamie Arnold will present at upcoming investor conferences.
Mr. Frantz and Mr. Arnold are scheduled to present at the Jefferies Global Healthcare Conference in New York City on Tuesday, June 5, 2018, at 4:00 PM EDT.
Mr. Frantz and Mr. Arnold are also scheduled to present at the William Blair and Company 38th Annual Growth Stock Conference in Chicago, IL on Tuesday, June 12, 2018 at 1:30pm CDT.
Live audio-only webcasts and related presentation materials will be available on the investor relations section of the Company’s website at investor.qsii.com.Quality Systems, Inc., known to its clients as NextGen Healthcare, provides a range of software, services, and analytics solutions to medical and dental group practices. The company’s portfolio delivers foundational capabilities to empower physician success, enrich the patient care experience, and enable the transition to value-based healthcare. Visit http://www.qsii.com and http://www.nextgen.com for additional information.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Clovis Oncology to Present at the Bank of America Merrill Lynch Healthcare Conference 2018

Posted by fidest press agency su sabato, 12 maggio 2018

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J. Mahaffy, Chief Executive Officer and President, will present at the Bank of America Merrill Lynch Healthcare Conference 2018 on Thursday, May 17, 2018 at 10:00 AM Pacific Time. The conference will be held at the Encore Hotel in Las Vegas, Nevada.
A live webcast of the presentation can be accessed through the investor relations section of the Company’s website at http://www.clovisoncology.com. Following the live presentation, a replay of the webcast will be available on the Company’s website for 30 days.
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops, with partners, diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado, and has additional offices in San Francisco, California and Cambridge, UK. Please visit http://www.clovisoncology.com for more information.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Aerpio Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference

Posted by fidest press agency su venerdì, 23 marzo 2018

Aerpio Pharmaceuticals, Inc. (OTCQB: ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced that Chief Executive Officer, Stephen Hoffman, M.D., Ph.D., will present at the 17th Annual Needham Healthcare Conference on Tuesday, March 27, 2018 at 3:00 p.m. Eastern Time in New York, NY. Dr. Hoffman will provide a corporate overview and business update.
Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases. The Company’s lead compound, AKB‐9778, is a small molecule activator of the Tie2 pathway and is in clinical development for the treatment of non-proliferative diabetic retinopathy. http://www.aerpio.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

ArQule to Present at the 17th Annual Needham Healthcare Conference on March 27, 2018

Posted by fidest press agency su venerdì, 23 marzo 2018

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will present at the 17th Annual Needham Healthcare Conference on March 27th, 2018, at 3:30 p.m. ET at the Westin Grand Central Hotel in New York, New York.You can access the live webcast of the presentation via the “Investors & Media” section of our website, http://www.arqule.com, under “Events & Presentations.” A replay of the webcast will be available shortly after the conclusion of the presentation.
ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases. ArQule’s mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of our patients. Our clinical-stage pipeline consists of five drug candidates, all of which are in targeted, biomarker-defined patient populations, making ArQule a leader among companies our size in precision medicine. ArQule’s proprietary pipeline includes: Derazantinib, a multi-kinase inhibitor designed to preferentially inhibit the fibroblast growth factor receptor (FGFR) family, in a registrational trial for iCCA; Miransertib (ARQ 092), a selective inhibitor of the AKT serine/threonine kinase, in a phase 1/2 company sponsored study for Overgrowth Diseases, in a phase 1 study for ultra-rare Proteus syndrome conducted by the National Institutes of Health (NIH), as well as in multiple oncology indications; ARQ 751, a next generation AKT inhibitor, in phase 1 for patients with AKT1 and PI3K mutations; and ARQ 761, a β-lapachone analog being evaluated as a promoter of NQO1-mediated programmed cancer cell necrosis, in phase 1/2 in multiple oncology indications in partnership with the University of Texas Southwestern Medical Center. In addition, we have advanced ARQ 531, an investigational, orally bioavailable, potent and reversible inhibitor of both wild type and C481S-mutant BTK, in phase 1 for patients with B-cell malignancies refractory to other therapeutic options. ArQule’s current discovery efforts are focused on the identification and development of novel kinase inhibitors, leveraging the Company’s proprietary library of compounds. You can follow us on Twitter and LinkedIn.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

PAVmed to Present at the 28th Annual Oppenheimer Healthcare Conference

Posted by fidest press agency su venerdì, 16 marzo 2018

PAVmed Inc. (Nasdaq: PAVM, PAVMW) (the “Company”), a highly differentiated, multiproduct medical device company, today announced that Lishan Aklog, M.D., PAVmed’s Chairman and Chief Executive Officer, will present at the 28th Annual Oppenheimer Healthcare Conference on Tuesday, March 20, 2018 at 3:55 p.m. Eastern time. Dr. Aklog will provide a corporate overview, discuss the Company’s innovative business model and review PAVmed’s lead products. The conference will be held March 20-21, 2018 at the Westin New York Grand Central in New York City.Dr. Aklog’s presentation will be webcast live and available for replay in the Events and Presentations section of the Company’s website at ir.pavm.com/events-presentations.
PAVmed Inc. is a highly differentiated, multiproduct medical device company employing a unique business model designed to advance innovative products to commercialization much more rapidly and with significantly less capital than the typical medical device company. This proprietary model enables PAVmed to pursue an expanding pipeline strategy with a view to enhancing and accelerating value creation. PAVmed’s diversified pipeline of products address unmet clinical needs encompassing a broad spectrum of clinical areas with attractive regulatory pathways and market opportunities. Its three lead products provide groundbreaking approaches to carpal tunnel syndrome (CarpX™), vascular access (PortIO™) and pediatric ear infections (DisappEAR™). The company is also developing innovative products in other areas, such as medical infusions and tissue ablation, while seeking to further expand its pipeline through engagements with clinician innovators and leading academic medical centers. For further information, please visit http://www.pavmed.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Award-Winning Healthcare System Installs Carestream’s Clinical Collaboration Platform to Enhance Its Image Management Workflow

Posted by fidest press agency su giovedì, 8 febbraio 2018

CARESTREAMDickinson County Healthcare System (Iron Mountain, Mich.) — a recipient of multiple healthcare quality awards — implemented Carestream Health’s Clinical Collaboration Platform (see video link) that features enterprise imaging, vendor-neutral archiving and Vue Motion enterprise viewer module. The Dickinson County system includes a community hospital and five satellite clinics.
“After evaluating several different PACS systems we selected Carestream because its fully featured platform is easy to use and offers the ability to read all modalities from a single workstation,” said Sherry Koepp, the healthcare system’s Manager of Imaging Services.The hospital’s Clinical Collaboration Platform supports lesion management, 3D tools, breast tomography, cardiac CT, breast MR and post processing. It also allows radiologists to read multiple modalities from a single workstation. The radiologists’ reading worklist is color coded so they can easily prioritize STAT reads over high priority or routine exams.Carestream’s advanced features are part of a unified platform that includes vendor-neutral archiving (VNA). “Our original plan was to purchase a separate VNA but our Carestream healthcare IT specialist recommended that we expand our storage area network with Carestream’s VNA software. This significantly reduces our cost without any sacrifice in performance or security,” Ms. Koepp explains.Both radiologists and physicians benefit from the platform’s critical results notification capabilities. “Radiologists can contact physicians to discuss critical results and answer any questions, which is an important factor in optimizing patient care,” reports David Alexa, the healthcare system’s PACS Administrator. The hospital also implemented Carestream’s Vue Motion enterprise viewer, which offers convenient access to patients’ images, videos, waveforms and reports from FDA-approved mobile devices.“Our referring physicians appreciate the ability to view the report and key images on mobile devices. Our ENT, orthopaedic, pulmonary and other specialists use the viewer to aid in diagnosis and treatment for patients,” said Mr. Alexa.System administrators use Carestream’s Vue Beyond to improve departmental workflow. This platform provides real-time monitoring of metrics that include study volume, modality mix, patient type and report turnaround time.Carestream’s Clinical Collaboration Platform delivers standards-based data capture, management, archiving and distribution for imaging data across the healthcare enterprise. The platform’s unified core is the backbone that enables enterprise imaging and associates all data for each patient with a single patient record. This imaging data can be easily integrated within a healthcare facility’s EMR/EHR. (photo: CARESTREAM)

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »